A expansão do mercado da cannabis medicinal no Brasil e os desafios da regulação
2024

Expansion of the medical cannabis market in Brazil and regulatory challenges

publication Evidence: low

Author Information

Author(s): Cláudia Du Bocage Santos Pinto, Ângela Esher, Cátia Verônica dos Santos Oliveira, Claudia Garcia Serpa Osorio-de-Castro

Primary Institution: Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz

Conclusion

The regulatory framework for medical cannabis in Brazil is still developing, with significant challenges in ensuring safety and efficacy for patients.

Supporting Evidence

  • Brazil spent around BRL 165 million on public supply of cannabis-derived products from 2015 to mid-2023.
  • Only one cannabis-derived product is classified as a medicine in Brazil.
  • Anvisa has authorized the import of cannabis-containing products under specific regulations.
  • Only a few indications for cannabis use have high or moderate levels of evidence.

Takeaway

Brazil is trying to figure out how to safely use cannabis for medicine, but there are still a lot of rules and not enough proof that it works for many problems.

Potential Biases

There is a risk of bias due to the influence of social pressure and litigation on the availability of cannabis products.

Limitations

The study highlights the low quality of evidence for many potential uses of cannabis-based products and the lack of regulatory clarity.

Digital Object Identifier (DOI)

10.1590/0102-311XEN088624

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication